As of 2024-12-15, the EV/EBITDA ratio of Clovis Oncology Inc (CLVS) is -2.90. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLVS's latest enterprise value is 613.83 mil USD. CLVS's TTM EBITDA according to its financial statements is -211.35 mil USD. Dividing these 2 quantities gives us the above CLVS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 16.5x | 14.8x |
| Forward P/E multiples | 13.9x - 19.3x | 15.2x |
| Fair Price | (24.45) - (28.21) | (26.10) |
| Upside | -30210.1% - -34842.8% | -32239.1% |
| Date | EV/EBITDA |